Skip to main content
. 2022 Jan 20;43(34):3198–3208. doi: 10.1093/eurheartj/ehab841

Figure 1.

Figure 1

New targets for lipid-lowering therapies. Beyond low-density lipoprotein, lipoprotein(a) and triglyceride-rich lipoproteins or remnant lipoproteins have become actionable targets in lipid management. IDL, intermediate-density lipoprotein; VLDL, very low-density lipoprotein.